Boston Scientific Corp

Boston Scientific designs and manufactures medical devices for interventional procedures, selling to hospitals and physicians worldwide. The company generates revenue across three main segments: cardiovascular devices like stents and heart rhythm management systems, medsurg products including endoscopy and urology devices, and neuromodulation systems for chronic pain. BSX makes money by selling single-use and implantable devices, capitalizing on minimally invasive treatment trends that reduce recovery times compared to traditional surgery.

Boston Scientific has delivered strong growth through innovation in medical devices and strategic acquisitions expanding its product portfolio. The company benefits from demographic trends favoring minimally invasive procedures, recurring revenue from implantable devices, and geographic expansion. Risks include regulatory approval timelines for new products, reimbursement pressures from healthcare payers, intense competition, and potential product liability issues. The stock typically trades at premium valuations reflecting consistent revenue growth and margin expansion.

Boston Scientific competes with Medtronic, the largest medical device company offering cardiovascular, diabetes, and surgical products. Abbott Laboratories competes directly in cardiovascular devices, neuromodulation, and diagnostics. Johnson & Johnson through its MedTech division offers surgical and electrophysiology devices. In specific categories, BSX also faces competition from Edwards Lifesciences in structural heart and Intuitive Surgical in minimally invasive surgical systems.

Boston Scientific has built a diversified portfolio across multiple high-growth medical device categories, reducing dependence on any single product line. The company has demonstrated consistent ability to integrate acquisitions and drive innovation, launching new devices that capture market share in cardiology, electrophysiology, and endoscopy. Its focus on less invasive procedures positions it well for secular trends in healthcare delivery, while global expansion provides runway for growth beyond mature U.S. markets.

BSX last closed at $69.78, up 2.39% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $67.56 and a high of $109.50. The current price represents 5% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 40 analysts covering BSX, the consensus rating is Strong Buy — 37 rate it a buy, 3 hold, and 0 sell. The average price target sits at $136.36, implying 95% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Boston Scientific Corp generated $19.97B in revenue during fiscal year 2026, with $2.88B reaching the bottom line as net income. The net profit margin of 14.4% is solid for its sector.

BSX trades at a P/E ratio of 35.63 on trailing earnings of $1.94 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -27.36% (3M), -28.93% (6M), -32.31% (1Y), -26.32% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether BSX is outperforming or lagging the broader market.